Parametric Portfolio Associates’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Parametric Portfolio Associates’s Portfolio CYT Stock Details CYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$105K	Buy	+27,924	New	+$159K	﹤0.01%	3557

Other funds holding CYT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OMC

OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parametric Portfolio Associates's CYT Position: Q1 2022 in Review

Parametric Portfolio Associates opened a new position in Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2022: 27,924 shares worth $105K. The stake represents ﹤0.01% of the portfolio and ranks #3557 among its holdings.

52 funds tracked by Wall St. Rank hold CYT as of Q1 2022.

Parametric Portfolio Associates held 27,924 shares of Cyteir Therapeutics, Inc. Common Stock worth $105K as of Q1 2022.
Cyteir Therapeutics, Inc. Common Stock was a new Parametric Portfolio Associates position in Q1 2022.
Cyteir Therapeutics, Inc. Common Stock made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3557 holding.
52 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.